Both US List And Net Drug Price Increases Have Been Substantial, JAMA Study Finds
Executive Summary
A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.
You may also be interested in...
FDA Relying More On Predictive Analytics To Help Monitor Quality Risks Of Sites During Pandemic
Analytics tool plays key role in helping agency oversee quality of 1,800 newly registered hand sanitizer facilities despite travel restrictions.
JAMA Drug Pricing Studies: Moving The Needle Or Looking At The Past?
Studies show net prices increases, R&D spending lower than often cited, and better profit margins other industries. But pharma pushes back with concerns about study designs and maintains the picture has changed in more recent years.
Pharma Outpaces All Other Industries In US Federal Lobbying Spending
Over the past 20 years, the pharmaceutical industry has notched a series of wins with its extraordinary federal lobbying expenditures and campaign contributions. A new JAMA Internal Medicine study examines spending from 1999-2018.